NASDAQ$QTRX
Quanterix Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Announced Q4 2020 financial results, with non-GAAP revenue increasing by 36% compared to the prior year.
Quanterix reported Q4 GAAP revenue of $26.1 million and non-GAAP revenue of $21.6 million, representing a 36% increase compared to the previous year. The company is focusing on the long-term impact of COVID-19 on human health and scaling its operations to meet the growing demand for ultra-sensitive protein analytical tools.
- Q4 GAAP revenue including Grant Revenue was $26.1M.
- Q4 non-GAAP revenue was $21.6M, a 36% increase versus prior year.
- The company is addressing the pandemic crisis and advances in Alzheimer's therapies.
- Quanterix is scaling to support this unprecedented opportunity in precision health.
Headline financials
Revenue & EPS history
Quanterix · Revenue · Quarterly
$26.1M
Revenue by segment
Quanterix · $20.4M total across 3 segments · Q3 2023
- Product Revenue$19.7M—96.4%
- Grant Revenue$499K—2.4%
- Collaboration and License$237K—1.2%
Forward guidance
Quanterix is entering 2021 on strong footing, scaling to support the unprecedented opportunity in precision health, and focusing on analytical tools to support disease studies, diagnostics, and drug development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-3.6%
Avg return
Earnings day
-5.0%
Avg return
5 days after
-1.1%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+18.1%
Q3 2020
Best reaction
-57.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -15.2% | -0.6% | |
| Q4 2025 | -7.1% | -20.1% | -40.1% | |
| Q3 2025 | -2.0% | +12.1% | +47.5% | |
| Q1 2025 | -19.3% | -16.4% | +8.0% | |
| Q4 2024 | -1.8% | -0.8% | -29.3% | |
| Q3 2024 | -19.0% | -25.3% | -27.1% | |
| Q2 2024 | -13.5% | -11.7% | -5.0% | |
| Q1 2024 | -1.7% | -0.7% | -7.0% | |
| Q4 2023 | -2.8% | +20.1% | +0.3% | |
| Q3 2023 | -1.7% | -10.6% | +1.2% | |
| Q2 2023 | +11.0% | +9.5% | +15.4% | |
| Q1 2023 | +1.9% | -6.8% | +33.5% | |
| Q4 2022 | +5.9% | -1.4% | -1.6% | |
| Q3 2022 | -2.1% | +31.4% | +35.9% | |
| Q2 2022 | -57.3% | -40.1% | -45.8% | |
| Q1 2022 | -16.6% | +1.6% | -6.1% | |
| Q4 2021 | -3.1% | -11.9% | -13.5% | |
| Q3 2021 | +3.1% | -1.5% | -32.6% | |
| Q2 2021 | -5.0% | -6.7% | -6.4% | |
| Q1 2021 | +0.7% | -10.2% | +3.4% | |
| Q4 2020 | -20.8% | -18.5% | -25.7% | |
| Q3 2020 | +18.1% | +6.9% | +11.5% | |
| Q2 2020 | +8.5% | +2.6% | +1.3% | |
| Q1 2020 | +3.8% | -3.5% | -4.1% | |
| Q4 2019 | -7.0% | -20.3% | +7.8% | |
| Q3 2019 | +16.8% | +10.2% | +23.8% | |
| Q2 2019 | -5.4% | -17.5% | -17.3% | |
| Q1 2019 | -4.0% | -8.5% | +28.0% | |
| Q4 2018 | -1.1% | -2.7% | +10.3% | |
| Q3 2018 | -0.1% | -4.6% | +7.0% | |
| Q2 2018 | -1.3% | -0.5% | -0.9% | |
| Q1 2018 | +4.0% | +3.5% | -7.4% | |
| Q4 2017 | -1.2% | -8.6% | -1.7% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro